Taligantinib
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met) . Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma[1].
Product Specifications
CAS Number
2243235-80-3
UNSPSC
12352005
Target
C-Met/HGFR; VEGFR
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(C1(CC1)C(NC2=CC=C(C(F)=C2)OC3=CC=NC4=CC(OCCCN5CCOCC5)=C6OCCOC6=C43)=O)NC7=CC=C(C=C7)F
Molecular Formula
C35H34F2N4O7
Molecular Weight
660.66
References & Citations
[1]Zhang Q, et al. Dioxanoquinazoline, dioxanoquinazoline-type compound, preparation method therefor and use thereof. WO2018153293A1. 2018-08-30.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Met; VEGFR2/KDR/Flk-1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD35 / CR1 (E11), CF640R conjugate, 0.1mg/mL
Major Vault Protein (MVP) (1032), CF405S conjugate, 0.1mg/mL
Fibronectin (HFN7.1), CF640R conjugate, 0.1mg/mL
CD44 Standard (DF1485), CF568 conjugate, 0.1mg/mL
C1QA / Complement C1q A-Chain (C1QA/2953), CF568 conjugate, 0.1mg/mL
